Everett Harris & Co. CA Has $3.19 Million Stock Holdings in Baxter International Inc. $BAX

Everett Harris & Co. CA lessened its holdings in shares of Baxter International Inc. (NYSE:BAX) by 66.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 166,896 shares of the medical instruments supplier’s stock after selling 332,637 shares during the period. Everett Harris & Co. CA’s holdings in Baxter International were worth $3,189,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Dodge & Cox grew its holdings in Baxter International by 10.1% during the 3rd quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock worth $1,306,915,000 after acquiring an additional 5,274,750 shares during the period. Geode Capital Management LLC raised its holdings in Baxter International by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after purchasing an additional 972,891 shares during the period. Greenhaven Associates Inc. raised its holdings in Baxter International by 70.0% in the fourth quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock worth $204,347,000 after purchasing an additional 4,404,874 shares during the period. Ameriprise Financial Inc. raised its holdings in Baxter International by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after purchasing an additional 97,687 shares during the period. Finally, Thompson Siegel & Walmsley LLC raised its holdings in Baxter International by 12.0% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 3,328,202 shares of the medical instruments supplier’s stock worth $63,602,000 after purchasing an additional 356,612 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Price Performance

Shares of NYSE BAX opened at $19.24 on Tuesday. The firm has a market cap of $9.94 billion, a PE ratio of -9.03, a PEG ratio of 3.12 and a beta of 0.64. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $32.04. The company has a fifty day moving average price of $17.93 and a 200 day moving average price of $18.80. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The business had revenue of $2.70 billion during the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter last year, the firm earned $0.62 earnings per share. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Research analysts predict that Baxter International Inc. will post 1.92 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, May 29th. Baxter International’s dividend payout ratio is currently -1.88%.

Analysts Set New Price Targets

BAX has been the topic of several analyst reports. Stifel Nicolaus cut their target price on shares of Baxter International from $20.00 to $19.00 in a report on Friday, May 1st. Evercore cut their target price on shares of Baxter International from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Zacks Research upgraded shares of Baxter International from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Jefferies Financial Group cut their target price on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Baxter International in a report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $19.73.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.